|
?:abstract
|
-
The World Health Organisation (WHO) announced on the 11th March 2020, a pandemic caused by a novel beta-coronavirus SARS-CoV-2, designated COVID-19. The virus emerged in December 2019 in Wuhan, China has spread across the world to be classed as a global pandemic. The traditional use of medicines from plants can be traced back to 60,000 years. Global interest in development of drugs from natural products has increased greatly during the last few decades. Essential oils (EOs) have been studied through the centuries and are known to possess various pharmaceutical properties. In the present review, we have highlighted the current biology, epidemiology, various clinical aspects, different diagnostic techniques, clinical symptoms, and management of COVID-19. An overview of the antiviral action of EOs along with their proposed mechanism of action and in silico studies conducted, are described. The reported studies of EOs antiviral activity highlight the baseline data about the additive, and/or synergistic effects among primary or secondary phytoconstituents found in individual oils, combinations or blends of oils and between EOs and antiviral drugs. It is hoped that further research will provide better insights of EOs potential to limit viral infection and aids in providing a solutions through natural, therapeutically active agents. lupus erythematosus; SKP2, s-phase kinase-associated protein 2; TNF-α, tumour necrosis factor alpha; TPA, Tetradecanoyl-phorbol acetate; WHO, The World Health Organisation.
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}